CNS autoimmune inflammation leads to increased bioluminescence in oLucR mice at clinical onset of disease. (a) EAE disease scores in MOG-immunized oLucR animals (mean ± SEM, n = 5). (b) Ratio of mean CNS-specific bioluminescence between MOG-immunized and control mice imaged in an IVIS every 2 to 3 days after immunization. Data are representative of three independent experiments (n = 15). The red line indicates the baseline photon emission before MOG immunization. (c) Linear correlation between day of clinical onset and increase of bioluminescence in MOG-immunized oLucR mice (n = 15, Pearson’s correlation coefficient = 0.9989). The three mice with disease onset around day 40 did not develop clinically overt EAE after the initial EAE induction and therefore were re-immunized with MOG peptide after 1 month. (d) Ratio of mean CNS-specific bioluminescence between PT-treated and control mice. oLucR mice were injected with 300 ng PT at day 0 and 2 and bioluminescence acquired over time (n = 5). The red line indicates baseline photon emission before PT administration.